Circulating MiRNA Signature Predicts Cancer Incidence in Lynch Syndrome-A Pilot Study

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2024 Mar 29

PMID 38551987

Authors

Tero Sievanen

Tiina Jokela

Matti Hyvarinen

Tia-Marje Korhonen

Kirsi Pylvanainen

Jukka-Pekka Mecklin

Juha Karvanen

Elina Sillanpaa

Toni T Seppala

Eija K Laakkonen

Affiliations

Soon will be listed here.

Abstract

Prevention Relevance: The development of cancer risk prediction models is key to improving the survival of patients with LS. This pilot study describes a serum miRNA signature-based risk prediction model that predicts LS cancer incidence within 4 years, although further validation is required.

References

Snel B, Lehmann G, Bork P, Huynen M . STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 2000; 28(18):3442-4. PMC: 110752. DOI: 10.1093/nar/28.18.3442. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Seppala T, Burkhart R, Katona B . Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. BJS Open. 2023; 7(3). PMC: 10172688. DOI: 10.1093/bjsopen/zrad023. View

Sticht C, de la Torre C, Parveen A, Gretz N . miRWalk: An online resource for prediction of microRNA binding sites. PLoS One. 2018; 13(10):e0206239. PMC: 6193719. DOI: 10.1371/journal.pone.0206239. View

Peltomaki P, Nystrom M, Mecklin J, Seppala T . Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023; 164(5):783-799. DOI: 10.1053/j.gastro.2022.08.058. View

Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H . Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clin Cancer Res. 2015; 21(18):4234-42. PMC: 4573815. DOI: 10.1158/1078-0432.CCR-14-2793. View

Mori M, Ludwig R, Garcia-Martin R, Brandao B, Kahn C . Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease. Cell Metab. 2019; 30(4):656-673. PMC: 6774861. DOI: 10.1016/j.cmet.2019.07.011. View

Pichler M, Ress A, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D . MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br J Cancer. 2014; 110(6):1614-21. PMC: 3960623. DOI: 10.1038/bjc.2014.51. View

Sur D, Advani S, Braithwaite D . MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:915226. PMC: 9676370. DOI: 10.3389/fmed.2022.915226. View

10.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

11.

Raut J, Schottker B, Holleczek B, Guo F, Bhardwaj M, Miah K . A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction. Nat Commun. 2021; 12(1):4811. PMC: 8355103. DOI: 10.1038/s41467-021-25067-8. View

12.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

13.

Adam R, Poel D, Moreno L, Spronck J, de Back T, Torang A . Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes. Mol Oncol. 2022; 16(14):2693-2709. PMC: 9297751. DOI: 10.1002/1878-0261.13210. View

14.

Wikberg M, Myte R, Palmqvist R, van Guelpen B, Ljuslinder I . Plasma miRNA can detect colorectal cancer, but how early?. Cancer Med. 2018; 7(5):1697-1705. PMC: 5943420. DOI: 10.1002/cam4.1398. View

15.

Mathers J, Elliott F, Macrae F, Mecklin J, Moslein G, McRonald F . Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. Cancer Prev Res (Phila). 2022; 15(9):623-634. PMC: 9433960. DOI: 10.1158/1940-6207.CAPR-22-0044. View

16.

Sievanen T, Korhonen T, Jokela T, Ahtiainen M, Lahtinen L, Kuopio T . Systemic circulating microRNA landscape in Lynch syndrome. Int J Cancer. 2022; 152(5):932-944. PMC: 10092425. DOI: 10.1002/ijc.34338. View

17.

Huang H, Lin Y, Li J, Huang K, Shrestha S, Hong H . miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2019; 48(D1):D148-D154. PMC: 7145596. DOI: 10.1093/nar/gkz896. View

18.

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

19.

Dominguez-Valentin M, Sampson J, Seppala T, Ten Broeke S, Plazzer J, Nakken S . Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2019; 22(1):15-25. PMC: 7371626. DOI: 10.1038/s41436-019-0596-9. View

20.

Slattery M, Lee F, Pellatt A, Mullany L, Stevens J, Samowitz W . Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod Pathol. 2017; 30(8):1152-1169. PMC: 5537006. DOI: 10.1038/modpathol.2017.38. View